Krajska Nemocnice T Bati a.s.

The clinic conducts studies aimed at improving procedural safety and diagnostic accuracy for acute conditions, evaluating novel fluid‑management strategies during neurosurgery and assessing minimally invasive approaches for stroke and pulmonary embolism.

• Acute non‑cardioembolic ischemic stroke
• Intermediate‑high risk pulmonary embolism
• Elective neurosurgery for brain conditions
• Post‑operative complications after neurosurgical procedures

Krajska Nemocnice T Bati a.s. supports these technique‑focused trials to enhance patient outcomes.

Trials target major heart and vascular events, testing innovative anti‑inflammatory and antithrombotic agents to reduce recurrence of myocardial infarction and prevent ischemic stroke after acute episodes.

• Anterior ST‑elevation myocardial infarction
• Non‑ST‑elevation myocardial infarction
• Ischemic stroke after transient ischemic attack
• Major adverse cardiovascular events (MACE)

Research at the oncology clinic integrates cardiovascular expertise to address these life‑threatening conditions.

Studies evaluate the long‑term efficacy of biologic therapies for inflammatory bowel disorders, aiming to induce remission and improve quality of life for patients with Crohn’s disease and ulcerative colitis.

• Crohn’s disease
• Ulcerative colitis
• Moderately to severely active ulcerative colitis

The site’s multidisciplinary team collaborates to bring cutting‑edge treatments to patients with gastrointestinal inflammation.

Oncologic trials explore targeted and immunotherapies for various solid tumours, seeking better response rates and longer progression‑free survival in conditions such as non‑small cell lung cancer, ER+/HER2‑ advanced breast cancer, and head and neck squamous cell carcinoma.

• Non‑small cell lung cancer with HER2 mutation
• ER+/HER2‑ advanced breast cancer
• Head and neck squamous cell carcinoma
• Recurrent/metastatic solid tumours

Krajska Nemocnice T Bati a.s.’s oncology clinic leverages these trials to expand therapeutic options for cancer patients.

Investigations focus on disease‑modifying agents for multiple sclerosis, aiming to slow disability progression and reduce relapse rates in both relapsing‑remitting and secondary progressive forms.

• Relapsing‑remitting multiple sclerosis
• Non‑relapsing secondary progressive multiple sclerosis
• Patients at high risk of disability progression

Through these studies, the clinic contributes to advancing neuro‑immunology treatments.